<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2366">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04373707</url>
  </required_header>
  <id_info>
    <org_study_id>2020-001709-21</org_study_id>
    <nct_id>NCT04373707</nct_id>
  </id_info>
  <brief_title>Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19</brief_title>
  <acronym>COVI-DOSE</acronym>
  <official_title>Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grand Est Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Saint-Etienne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Worldwide observational studies indicate a significant prothrombogenic effect associated with
      SARS-CoV-2 infection with a high incidence of venous thromboembolism (VTE), notably
      life-threatening pulmonary embolism.

      According to recommendations for acute medical illnesses, all COVID-19 hospitalized patients
      should be given VTE prophylaxis such as a low molecular weight heparin (LMWH). A standard
      prophylactic dose (eg. Enoxaparin 4000IU once daily) could be insufficient in obese patients
      and VTE has been reported in patients treated with a standard prophylactic dose.

      In COVID-19 patients, guidelines from several international societies confirm the existence
      of an hypercoagulability and the importance of thromboprophylaxis but the &quot;optimal dose is
      unknown&quot; and comparative studies are needed.

      In view of these elements, carrying out a trial comparing various therapeutic strategies for
      the prevention of VTE in hospitalized patients with COVID-19 constitutes a health emergency.

      Thus, we hypothesize that an increased prophylactic dose of weight-adjusted LMWH would be
      greater than a lower prophylactic dose of LMWH to reduce the risk of life-threatening VTE in
      hospitalized patients. The benefit-risk balance of this increase dose will be carefully
      evaluated because of bleeding complications favored by possible renal / hepatic dysfunctions,
      drug interactions or invasive procedures in COVID-19 patients.

      This multicenter randomized (1:1) open-label controlled trial will randomize hospitalized
      adults with COVID-19 infection to weight-adjusted prophylactic dose vs. lower prophylactic
      dose of LMWH.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter randomized (1:1) controlled open-label trial, stratified on disease severity (admission to ICU or not)</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Venous thromboembolism</measure>
    <time_frame>28 days</time_frame>
    <description>Risk of deep vein thrombosis or pulmonary embolism or venous thromboembolism-related death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>28 days</time_frame>
    <description>Risk of major bleeding defined by the ISTH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding and Clinically Relevant Non-Major Bleeding</measure>
    <time_frame>28 days</time_frame>
    <description>Risk of Major Bleeding and Clinically Relevant Non-Major Bleeding Defined by the ISTH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Clinical Benefit</measure>
    <time_frame>28 days and 2 months</time_frame>
    <description>Risk of Venous Thromboembolism and Major Bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Thromboembolism at other sites</measure>
    <time_frame>28 days</time_frame>
    <description>Risk of venous thrombosis at other sites: e.g. superficial vein, catheters, hemodialysis access, ECMO, splanchnic, encephalic, upper limb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Thrombosis</measure>
    <time_frame>28 days</time_frame>
    <description>Risk of arterial thrombosis at any sites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-Cause Mortality</measure>
    <time_frame>28 days and 2 months</time_frame>
    <description>Risk of all-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors associated with the risk of venous thromboembolism</measure>
    <time_frame>28 days</time_frame>
    <description>Identification of associations between the risk of venous thromboembolism and clinical (eg. past medical history of thrombosis, cardiovascular risk factors, treatments, severity of COVID-19) and laboratory variables (e.g. D-dimers, fibrinogen, CRP) collected in the eCRF</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">602</enrollment>
  <condition>COVID</condition>
  <condition>Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <condition>Deep Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>Low Prophylactic Dose of Low Molecular Weight Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin, Tinzaparin, Nadroparin, Dalteparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Weight-Adjusted Prophylactic Dose Low Molecular Weight Heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enoxaparin, Tinzaparin, Nadroparin, Dalteparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>For example (Enoxaparin):
4000IU twice a day in patients &lt;50kg
5000IU twice a day in patients 50-70kg
6000IU twice a day in patients 70-100kg
7000IU twice a day in patients above 100kg</description>
    <arm_group_label>Weight-Adjusted Prophylactic Dose Low Molecular Weight Heparin</arm_group_label>
    <other_name>Tinzaparin</other_name>
    <other_name>Nadroparin</other_name>
    <other_name>Dalteparin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>For example (Enoxaparin): From 4000IU once a day in patients admitted in medical ward to 4000IU twice a day in patients admitted in the ICU. In patients with severe renal insufficiency (GFR=15-30 mL/min/1.73m²), LMWH doses will be reduced by 50%.</description>
    <arm_group_label>Low Prophylactic Dose of Low Molecular Weight Heparin</arm_group_label>
    <other_name>Tinzaparin</other_name>
    <other_name>Nadroparin</other_name>
    <other_name>Dalteparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient hospitalized for a probable/confirmed COVID-19 infection (confirmed by
             serology/polymerase chain reaction or by radiologic signs of COVID-19 pneumonia in the
             setting of clinical and laboratory abnormalities suggestive of a SARS-CoV-2 infection)

          -  Signed informed consent

          -  Patient affiliated to the Social Security

        Exclusion Criteria:

          -  Renal insufficiency with a GFR&lt;15 mL/min/1.73m²

          -  Acute kidney injury KDIGO3

          -  Prophylactic dose of low molecular weight heparin for more than 3 days

          -  Curative dose of low molecular weight heparin for more than 1 day

          -  Recurrent catheter/hemodialysis access thromboses

          -  ECMO required in the next 24h

          -  Contraindication to low molecular weight heparin

          -  High bleeding risk (e.g. uncontrolled severe systemic hypertension, recent major
             bleeding, disseminated intravascular coagulopathy, thrombocytopenia &lt; 75G/L)

          -  History of heparin-induced thrombocytopenia

          -  Contraindication to blood-derived products

          -  Impossibility to perform a doppler ultrasound of the lower limbs (e.g. above the knee
             amputation, severe burn injuries)

          -  Expected death in the next 48h

          -  Vulnerable subjects according to articles L. 1121-5, L. 1121-7 et L1121-8 of French
             Public Health Code
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>El Mehdi Siaghy</last_name>
    <role>Study Director</role>
    <affiliation>Research and Innovation Department, Nancy University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stéphane Zuily, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nancy Academic Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yohann Bernard, Res Proj Man</last_name>
    <phone>+33.3.83.15.52.72</phone>
    <email>y.bernard@chru-nancy.Fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïda Khaled-Jousselin, Res Proj Man</last_name>
    <phone>+33.3.83.15.52.77</phone>
    <email>s.khaled-jousselin@chru-nancy.Fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amiens Academic Hospital</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simon Soudet</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Besançon Academic Hospital</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Meneveau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brest Academic Hospital</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francis Couturaud</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Civil Hospital</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wael Younès</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dijon Academic Hospital</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Béatrice Terriat</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille Academic Hospital</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabrielle Sarlon-Bartoli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Metz-Thionville Regional Hospital</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline Robert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montpellier Academic Hospital</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle Quéré</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emile Muller Hospital</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amer Hamadé</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nancy Academic Hospital</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane Zuily</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>George Pompidou European Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Sanchez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Etienne Academic Hospital</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Mismetti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Strasbourg Academic Hospital</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique Stephan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toulouse Academic Hospital</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra Bura-Rivière</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Venous Thromboembolism</keyword>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Deep Vein Thrombosis</keyword>
  <keyword>Low Molecular Weight Heparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Nadroparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

